NeurAxis, Inc. (NRXS)

In October 2025, NeurAxis received FDA clearance for treating pain in functional dyspepsia with associated nausea in adults. In November and December 2025, new medical policy coverage in Michigan added 566,000 covered lives, and a major national health insurer expanded access to approximately 45 million additional covered lives. In December 2025, NeurAxis secured a Veterans Affairs Federal Supply Schedule contract. In January 2026, the AMA Category I CPT® Code for PENFS procedures became effective. NeurAxis reported strong financial results for Q3 2025 with 22% revenue growth, and for Q4 and FY2025 with revenues increasing 27% and 33%, respectively. In April 2026, the CFO and CEO made open-market share purchases, and NeurAxis announced a preferred stock dividend on April 10, 2026.

There is no explicit information indicating demand seasonality for NeurAxis, Inc.'s products and services.

NeurAxis, Inc. is a medical technology company focused on developing and commercializing neuromodulation therapies for chronic conditions in children and adults. The company operates in the Healthcare sector, specifically in the surgical and medical instrument manufacturing industry, advancing science and utilizing evidence-based medicine to promote its PENFS technology. Its primary product is IB-Stim, an FDA-cleared neuromodulation device for functional abdominal pain associated with IBS, functional dyspepsia, and FD-related nausea in patients aged 8 years and older. NeurAxis also offers a rectal expulsion device (RED) for detecting evacuation disorders, addressing unmet medical needs in gastrointestinal conditions, particularly in pediatric and adolescent patients.

NeurAxis, Inc. is headquartered in Carmel, Indiana, with a distribution center in Versailles, Indiana. Its market reach primarily extends across the United States, focusing on expanding medical policy coverage. As of December 2025, its PENFS technology covered approximately 100 million lives, following new medical policy coverage. The company has also secured a Veterans Affairs Federal Supply Schedule (FSS) contract.

NeurAxis, Inc.'s brand reputation has been positively influenced by FDA clearances for IB-Stim, the implementation of a Category I CPT code for PENFS procedures, expanded insurance coverage, and the inclusion of its PENFS technology in clinical practice guidelines for Functional Abdominal Pain (FAP) in IBS. These achievements demonstrate regulatory validation, enhance therapy credibility, broaden access, and solidify its reputation as an evidence-based therapy.

NeurAxis, Inc. has a mix of institutional, individual, and retail ownership. Institutional investors own approximately 11.77% to 14.06% of the stock, with major holders including AIGH Capital Management LLC and Vanguard Group Inc. Individual insiders own around 35.15%, with key shareholders including Brian Hannasch and Christopher Robin Brown. Retail investors hold approximately 50.79% of the stock.